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Abstract
Mangafodipir is a magnetic resonance imaging contrast agent with manganese superoxide dismutase (MnSOD)
mimetic activity. The MnSOD mimetic activity protects healthy cells against oxidative stress–induced detrimental
effects, e.g., myelosuppressive effects of chemotherapy drugs. The contrast property depends on in vivo disso-
ciation of Mn2+ from mangafodipir—about 80% dissociates after injection. The SOD mimetic activity, however, de-
pends on the intact Mn complex. Complexed Mn2+ is readily excreted in the urine, whereas dissociated Mn2+ is
excreted slowly via the biliary route. Mn is an essential but also a potentially neurotoxic metal. For more frequent
therapeutic use, neurotoxicity due to Mn accumulation in the brain may represent a serious problem. Replacement
of 4/5 of Mn2+ in mangafodipir with Ca2+ (resulting in calmangafodipir) stabilizes it from releasing Mn2+ after
administration, which roughly doubles renal excretion of Mn. A considerable part of Mn2+ release frommangafodipir
is governed by the presence of a limited amount of plasma zinc (Zn2+). Zn2+ has roughly 103 and 109 times higher
affinity than Mn2+ and Ca2+, respectively, for fodipir. Replacement of 80% of Mn2+ with Ca2+ is enough for binding a
considerable amount of the readily available plasma Zn2+, resulting in considerably less Mn2+ release and retention
in the brain and other organs. At equivalent Mn2+ doses, calmangafodipir was significantly more efficacious than
mangafodipir to protect BALB/c mice against myelosuppressive effects of the chemotherapy drug oxaliplatin.
Calmangafodipir did not interfere negatively with the antitumor activity of oxaliplatin in CT26 tumor–bearing syngenic
BALB/c mice, contrary calmangafodipir increased the antitumor activity.
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Introduction
Reactive oxygen species (ROS) are known to participate in patholog-
ical tissue damage, for instance, during treatment with chemother-
apy drugs in cancer patients [1]. The mitochondrial manganese
superoxide dismutase (MnSOD) plays a key role in the cellular defense
against reactive oxygen–derived free radicals by dismutating superoxide
anions (·O2
−), which normally leak from the respiratory chain during
mitochondrial reduction of O2 to H2O at fairly high amounts. Super-
oxide is also produced by nicotinamide adenine denucleotide phosphate
(NADPH) oxidase. Under normal circumstances, it represents an im-
portant mechanism by which neutrophils (NEU) kill invading bacteria
and fungi. However, ·O2
− is involved in many pathological conditions,
e.g., myocardial ischemia-reperfusion damage, doxorubicin myocardial
toxicity, atherosclerosis, and paracetamol hepatotoxicity.
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Yet as recently as 45 years ago, oxygen-derived radicals were not
thought to occur in living cells. Radicals were thought to be so reactive
and unselective that they could not occur in biologic systems. That
view changed dramatically in 1967 when Irwin Fridovich and Joe
McCord discovered the antioxidant enzyme SOD, a discovery that
without doubts belongs to one of the most important biologic discov-
eries during the last century. Mitochondrial MnSOD catalyzes dis-
mutation of ·O2
− at an extremely high rate (>109 M−1 s−1). The
reaction rate is actually close to the diffusion limit of ·O2
− [2], which
indicates the immense importance of MnSOD in the cellular defense
against oxidative stress. During pathological oxidative stress, the pro-
duction of ·O2
− exceeds the endogenous protective potential. More-
over, ·O2
− reacts readily with nitric oxide (NO·) to form highly toxic
peroxynitrite (ONOO−), which nitrates tyrosine residues of the
MnSOD enzyme and irreversibly inactivates the enzyme. Many years
ago, this mechanism was suggested to participate in chronic rejection
of human renal allografts [3] and recent results indicate nitration of
MnSOD to be an early step in paracetamol (acetaminophen)–induced
liver failure [4].
The balance between the mitochondrial antioxidant detoxification
system and ROS is finely maintained and low levels of mitochondrial
ROS are required by cells to modulate normal redox biology [5].
Excessive amounts of ROS, however, are believed to shorten life span
and to induce age-associated pathological conditions, such as carcino-
genesis, cardiovascular, and other diseases [6].
Although inflammatory processes secondary to oxidative stress
damage normal tissue, they may be beneficial to tumor tissue by cre-
ating growth factor–rich microenvironment and giving the cancerous
clones the need to start growing [7,8]. A body of evidence suggests
that whether MnSOD protects normal tissue it may paradoxically
make tumor tissue much more sensitive to radiation-induced [9,10]
and chemotherapy-induced [11] damaging effects.
The magnetic resonance imaging (MRI) contrast agent manganese
dipyridoxyl diphosphate (mangafodipir; MnDPDP) was approved in
1997 for use as a diagnostic MRI contrast agent in humans. Impor-
tantly, mangafodipir has also been shown to protect mice against
serious side effects of several chemotherapy drugs (doxorubicin,
oxaliplatin, and paclitaxel), without interfering negatively with the
anticancer effects of these drugs [12–15]. This includes protection
against serious reduction in leukocytes [14]. Mangafodipir (i.e., the
ready-to-use MRI contrast agent Teslascan) has been tested in one
colon cancer patient going through palliative treatment with a com-
bination of folinate, 5-fluorouracil, and oxaliplatin [16], and a first
clinical feasibility study in colon cancer patients going through adjuvant
5-fluorouracil plus oxaliplatin (FOLFOX) showing promising results
was recently published [17]. Mangafodipir has also been described to
protect mice against acetaminophen-induced liver failure [18,19].
Mn is an essential as well as potentially neurotoxic metal. It has
been known for many years that under conditions of chronic expo-
sure to high levels of Mn, a syndrome of extrapyramidal dysfunction
similar to Parkinson syndrome frequently occurs, although clinically a
different disease entity [20]. When a diagnostic MRI dose of manga-
fodipir is intravenously (i.v.) injected into humans, more than 80% of
the administered Mn is released [21,22]. Release of paramagnetic
Mn2+ is in fact a prerequisite for the diagnostic MRI properties of
mangafodipir [22,23]. However, the therapeutic effects of mangafo-
dipir depend on the intact Mn complex [24,25] because Mn under-
goes redox cycling (Mn2+/Mn3+) during the catalytic superoxide
dismutating cycle [2].
A considerable part of the release of Mn2+ from fodipir (DPDP) is
governed by the presence of a limited amount of free or loosely
bound zinc (Zn2+) in the plasma [21]. Zn2+ has roughly 1000 times
higher affinity than Mn2+ for fodipir [26], and replacement of Mn2+
with more loosely bound Ca2+ may hence reduce the amount of Mn2+
released after injection. Ca2+ has approximately 106 times lower affin-
ity than Mn2+ for fodipir [27].
The present paper describes how replacement of about 4/5 of the
Mn2+ within mangafodipir with Ca2+ considerably stabilizes it from
releasing potentially neurotoxic Mn and simultaneously increases the
therapeutic efficacy significantly.
Materials and Methods
Test Substances
Calmangafodipir [Ca4Mn(DPDP)5; Lot No. 11AK0105B; 98.8%
pure], mangafodipir (MnDPDP; Lot No.02090106; >99.9% pure),
fodipir (DPDP; Lot No. RDL02090206), and PLED [Lot No.
KER-AO-122(2)] were exclusively synthesized for PledPharma by
Albany Molecular Research, Inc (Albany, NY). The metabolites
MnPLED, ZnDPDP, and ZnPLED were gifts from GE Healthcare
(Oslo, Norway). Calfodipir (CaDPDP) was prepared by adding
equimolar amount of CaCl2 to a stock solution of fodipir (DPDP).
Ready-to-use Teslascan (10 mM containing 6 mM ascorbic acid) was
from GE Healthcare. Before injection, the test substances were dis-
solved in 0.9% NaCl solution to suitable strengths.
Oxaliplatin used in the myelosuppressive studies was from Sanofi-
aventis (Eloxatin, 5 mg/ml), and that used in the tumor studies was
from Teva (Hälsingborg, Sweden). Before injection, oxaliplatin was
diluted in 5% glucose to a suitable strength.
Animals
Male Wistar rats (approximately 250 g) used in the excretion studies
were from Taconic (Ry, Denmark), whereas male and female rats used
in the studies on Mn distributions in the brain and other selected
organs after repeated administration were from Charles River (Sulzfeld,
Germany). BALB/c female mice (6–8 weeks) used in the myelosuppressive
studies were from Charles River, and BALB/c mice (6–8 weeks) used
in the tumor studies were from Taconic. The animal experiments were
approved by the Ethical Committees on animal research.
Renal Excretion of Mn and Zn in Rats
In a first series of experiments, 10 male Wistar rats (approximately
250 g) were injected i.v., via one of the tail veins, with either 0, 0.125,
0.250, 0.500, or 0.750 ml of a 10 mM fodipir (DPDP) solution,
corresponding to 0, 5, 10, 20, and 30 μmol/kg.
In the second series of experiments, eight male Wistar rats (approx-
imately 250 g) were injected i.v., via one of the tail veins, with 0.25 ml
of a 50 mM calmangafodipir solution, containing 10 mM Mn2+ and
40 mMCa2+, or 0.25 ml of 10 mMmangafodipir, containing 10 mM
Mn2+, corresponding to an Mn2+ dose of 10 μmol/kg in both cases.
To obtain basal levels of Mn and Zn in urine, two additional (control)
rats received 0.25 ml of saline and were placed in metabolic cages for
urine collection over the same period of time.
After injection, the rats were immediately placed in metabolic
cages for urine collection over a period of up to 24 hours. The urine
samples were then stored at −80°C until Mn and Zn analysis. Before
analysis, the samples were thawed and extensively shaken to obtain
homogenous samples. A 5 ml of aliquot was taken from each sample
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and 5 ml concentrated nitric acid was added. The samples were
then resolved in a microwave oven and thereafter diluted with
distilled water to a final volume of 50 ml. The Mn and Zn con-
tents of each sample were analyzed by inductively coupled plasma
mass spectrometry. Identical samples of calmangafodipir and manga-
fodipir as those injected in the rats (i.e., 0.250 ml) were with-
drawn and injected into test tubes. These samples were treated in
an identical manner to that of the urine samples and analyzed for its
Mn content.
Organ Retention of Mn after Repeated Administration of
Calmangafodipir or Mangafodipir in Rats
Wistarmale and female rats were i.v. injected with either 0.9%NaCl,
72.0 μmol/kg mangafodipir (corresponding to 72.0 μmol/kg Mn), or
374.4 μmol/kg calmangafodipir (corresponding to 72.0 μmol/kg Mn)
three times a week for 13 weeks (each treatment group consisted of nine
males and nine females). Each dose of calmangafodipir corresponded to
about 36 times the assumed clinical dose. After the 13-week adminis-
tration period, the rats were killed and the brains and pancreas were
dissected out and approximately 0.5 g of samples were stored frozen
until Mn analysis. The Mn content of each sample was analyzed by
inductively coupled plasma mass spectrometry.
In Vivo Myeloprotective Effects of Calmangafodipir,
Mangafodipir, Teslascan, and MnPLED against
Oxaliplatin in BALB/c Mice
In a first series of experiments, three groups each consisting of five
female BALB/c mice were treated once intraperitoneally (i.p.) with
oxaliplatin at 7.5, 10.0, and 12.5 mg/kg oxaliplatin, respectively.
One day before (baseline) as well as 3 and 6 days after oxaliplatin
treatment, 50 μl of EDTA blood samples was taken from the orbital
venous plexus with a glass capillary. The blood samples were ana-
lyzed using the automated system CELL-DYN Emerald (Abbott
Diagnostics, Wiesenbaden, Germany) for the content of white blood
cells (WBC), lymphocytes (LYM), NEU, and platelets (PLC). CELL-
DYN Emerald is accredited for human blood samples. The used de-
vice is, however, especially calibrated for mouse blood samples. The
CELL-DYN Emerald mouse data obtained at the present laboratory
have repeatedly been compared with data from an accredited external
laboratory (device: XT2000I; Sysmex, Norderstedt, Germany). These
comparisons have always resulted in strong correlations regarding WBC,
LYM, and NEU (data not shown).
From the results (Figure 1), it was concluded that further experi-
ments testing the myeloprotective effects of calmangafodipir, manga-
fodipir, Teslascan, and MnPLED should be performed at 12.5 mg/kg
oxaliplatin and that blood cell sample analyses should be performed the
day before and 6 days after oxaliplatin administration in every mouse.
Thirty minutes before and 24 hours after oxaliplatin administration,
mice received saline, calmangafodipir [6.5 μmol/kg; Ca4Mn(DPDP)5],
mangafodipir (1.3 and 13.0 μmol/kg), Teslascan (13.0 μmol/kg), or
MnPLED (2.0 μmol/kg) i.v. (five mice in each group). A control group
received vehicle (5% glucose) instead of oxaliplatin and saline instead
of test substance.
An additional group of five animals received 6.5 μmol/kg (5 mg/kg)
calmangafodipir with a treatment schedule identical to the above
described experiments (calmangafodipir 30minutes before and 24 hours
after 12.5 mg/kg oxaliplatin; “double dose”). Another group of
five mice received just one calmangafodipir treatment, 6.5 μmol/kg,
Figure 1. The myelosuppressive effects of increasing single doses (7.5, 10.0, and 12.5 mg/kg) of oxaliplatin on (A) WBC, (B) LYM,
(C) NEU, and (D) PLC at 3 and 6 days after injection. Results expressed as mean ± SEM (n = 5 in each group).
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30 minutes before oxaliplatin (“single dose”). Two further groups of
mice receiving either vehicle (i.e., saline plus glucose) or oxaliplatin
(i.e., saline plus oxaliplatin) treatment were run in parallel.
The In Vitro Cytotoxic Activity of Calmangafodipir,
Mangafodipir, Fodipir, and Metabolites in CT26 Cells
The viability of cells was measured using the methylthiazoletetra-
zolium assay. Briefly, 8000 CT26 (mouse colon carcinoma) cells were
seeded per well on a 96-well plate and grown overnight in Roswell
Park Memorial Institute (RPMI) 1640 medium containing 10%
FBS, 2 mM L-glutamine, 100 UI/ml penicillin, and 100 μg/ml strep-
tomycin at 37°C in humidified air with 5% CO2.
In a first series of experiments, cells were exposed to increasing
concentrations of oxaliplatin (0.1–100 μM) for 48 hours at 37°C,
in the absence and presence of various concentrations of fodipir
(10, 30, and 100 μM).
In a second series of experiments, cells were then exposed for
48 hours to 1 to 1000 μM calmangafodipir, fodipir, PLED, calfodipir,
mangafodipir, MnPLED, ZnPLED, ZnDPMP, and CaCl2 at 37°C.
The viability of the cells was then assessed by adding 5 mg/ml
methylthiazoletetrazolium to a final concentration of 0.5 mg/ml and
incubating cells for a further 4 hours at 37°C. The blue formazan that
is formed by mitochondrial dehydrogenases of viable cells was then
dissolved overnight at 37°C by adding 10% sodium dodecyl sulfate and
10 mMHCl to a final concentration of 5% sodium dodecyl sulfate and
5 mMHCl. Finally, the absorbance of the solution was read at 570 nm
with a reference at 670 nm in a microplate reader Spectramax 340
(Molecular Devices, Sunnyvale, CA) connected to an Apple Macintosh
computer running the programSoftmax ProV1.2.0 (MolecularDevices).
Antitumor Effects of Oxaliplatin in CT26 Tumor–Bearing
Syngenic Mice in the Absence and Presence of Calmangafodipir
CT26 cells were grown in 75-cm2 culture flasks in RPMI 1640
medium containing 10% FBS, 2 mM L-glutamine, 100 UI/ml pen-
icillin, and 100 μg/ml streptomycin at 37°C in humidified air with
5% CO2. When the cells reached ∼50% confluency, they were har-
vested by trypsinization. Briefly, cells were washed with phosphate-
buffered saline (PBS; pH 7.3) and exposed to 0.05% trypsin/0.53 mM
EDTA at 37°C for ∼5 minutes. The trypsinization was stopped by
adding RPMI 1640 culture medium. Cells were counted and centri-
fuged at 200g for 5 minutes. Thereafter, they were washed in PBS,
centrifuged again, and resuspended in PBS at a concentration of 2 ×
106/350 μl for injection into mice. Briefly, each mouse was injected
subcutaneously in the back of the neck with 2 × 106 of CT26 cells at
day 0. After 7 days (day 7) when the tumors were detectable, the tumor
size was determined with a caliper and mice were grouped (five in each)
so that the sizes of the tumors were not statistically different by group.
Oxaliplatin ± calmangafodipir were injected and one group of mice
received vehicle (0.9% saline + 5% glucose) treatment alone.
In a first series of experiments, mice were injected i.v. with saline
or 50 mg/kg (65 μmol/kg) calmangafodipir 30 minutes before i.p.
administration of 20 mg/kg oxaliplatin (diluted in 5% glucose) or
5% glucose. These mice received in addition saline or 65.0 μmol/kg
(50 mg/kg) calmangafodipir 24 hours later (day 8). In another series
of experiments, mice were injected i.v. with saline or 6.5 μmol/kg
(5 mg/kg) or 32.5 μmol/kg (25 mg/kg) calmangafodipir 30 minutes be-
fore i.p. administration of 10 mg/kg oxaliplatin (diluted in 5% glucose)
or 5% glucose, and saline or 6.5 μmol/kg or 32.5 μmol/kg calmanga-
fodipir 24 hours later (day 8). The mice were killed on day 10 and the
tumors were excised, and wet weights (w.w.s) were determined.
Calculations, Presentation of Results, and Statistics
Renal excretion of Mn and Zn are presented as total 0- to 24-hour
urine content (expressed as μmol/kg ± SEM) and as percentage (±SEM)
of the injected dose. The organ content of Mn is expressed as μg/g w.w.
(±SEM). The myelosuppressive effects of oxaliplatin alone and in the
presence of calmangafodipir, mangafodipir, Teslascan, or MnPLED are
presented in graphs as relative changes from baseline (day −1) for the
blood cells (±SEM). The viability of CT26 cells in the presence of an
increasing concentration of the various test substances is presented as
concentration-response curves (mean ± SD). Where appropriate, the
individual curves were fitted to the sigmoidal normalized response
logistic equation (Graphpad Prism, version 5.02, La Jolla, CA). From
this analysis, the pD2 (negative log of the concentration of a drug that
produces half its maximal response, −log EC50) values of the test sub-
stances were calculated; pD2 values are presented together with 95%
confidence intervals. Statistical differences between the other treat-
ments, where appropriate, were tested by Student’s t test. P values
lower than .05 were considered as statistically significant differences.
Results
Renal Excretion of Mn and Zn after i.v. Administration of
Fodipir, Mangafodipir, and Calmangafodipir
Results from the first series of excretion experiments are shown in
Figure 2 (after subtracting basal Zn and Mn excretion). The basal 0- to
24-hour excretion of Zn in two control rats was found to be 0.852 and
0.771 μmol/kg body weight (b.w.), respectively. The 0- to 24-hour
Zn excretion more or less saturated around 4 μmol/kg Zn at a dose
of 10 μmol/kg fodipir. Fodipir had just minor effects on the Mn excre-
tion. As evident from this figure, fodipir is capable of increasing Zn
excretion considerably.
Results from the second series of experiments are shown in Figure 3.
Twenty-four hours after i.v. injection of 0.25 ml of 10 mM manga-
fodipir containing 2.59 μmol Mn, 0.60 ± 0.04 μmol Mn was recov-
ered in urine (Figure 3A), corresponding to 23.1 ± 1.4% of the
injected dose (Figure 3B). The corresponding figure after injection
of 0.25 ml of 50 mM calmangafodipir containing 2.52 μmol Mn
Figure 2. Zero- to twenty-four-hour Zn andMn renal excretion in rats
at increasing doses of fodipir (mean ± SEM; n = 10).
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was 1.27 ± 0.07 μmol Mn (Figure 3A), corresponding to 50.5 ± 2.6%
of the injected dose (Figure 3B). The difference between mangafo-
dipir and calmangafodipir was highly significant (P < .0001). The dif-
ference in renal Mn excretion was more or less reflected in the
difference in renal excretion of Zn, expressed as increased Zn excre-
tion, i.e., after the basal 24-hour excretion values (0.068 μmol) was
subtracted (Figure 3C ).
The present results demonstrate how replacement of about 4/5 of
the Mn2+ in mangafodipir with Ca2+, resulting in calmangafodipir,
stabilizes it from releasing Mn2+ after i.v. administration, which in turn
roughly doubles the amount of Mn2+ excreted in the urine.
Organ Retention of Mn after Repeated Administration of
Calmangafodipir or Mangafodipir
Results are shown in Figure 4. The Mn brain contents in NaCl-
treated control, mangafodipir-treated, and calmangafodipir-treated rats
were 0.38 ± 0.01, 0.99 ± 0.02, and 0.74 ± 0.01 μg/g w.w., respectively
(Figure 4A), whereas the corresponding Mn contents in the pancreas
were 1.66 ± 0.06, 5.54 ± 0.45, and 3.35 ± 0.19 μmol/kg, respectively
(Figure 4B). The levels in control animals were more or less identical
to those previously reported in rats by Ni et al. [28]. They reported
that the brain and pancreas in control animals contained 6.7 and
26.7 nmol/g w.w., corresponding to 0.37 and 1.5 μg/g w.w., respec-
tively. Although the Mn content of the liver was statistically signifi-
cantly elevated in the mangafodipir group (Figure 4C ), the relative
elevation was much less than those seen in the brain and pancreas. A
single diagnostic dose of mangafodipir (5 μmol/kg b.w.) is known to
cause rapid increase in the Mn content of both the pancreas and the
liver of rats—after 2 hours, theMn content of the pancreas was approx-
imately 10 times higher than the basal value, and the corresponding
value of liver was increased about 2 times [28]. Whereas Ni et al.
[28] found the Mn content still elevated after 24 hours in the pancreas
(about five times the basal value), it was back to baseline in the liver at
that time point. This presumably reflects the high capacity of the liver
to handle Mn and its important physiological role in Mn homeostasis.
This is further supported by the present results showing just a modest
increase in liver Mn after heavy exposure to mangafodipir.
As obvious from Figure 4, A and B, calmangafodipir resulted in
significantly less retention of Mn compared to mangafodipir, after
Figure 3. Increase in Mn content in 0- to 24-hour urine from rats injected with mangafodipir or calmangafodipir containing 2.59 μmol and
2.52 μmol Mn, respectively, expressed as (A) the total content of Mn (minus the basal content of Mn) and (B) the percentage of the
injected dose. (C) The increase in Zn content in 0- to 24-hour urine in the same animals. Results are expressed as mean ± SEM (n = 4 in
each group).
Figure 4. Mn content of the (A) brain, (B) pancreas, and (C) liver, respectively, after 39 doses of either NaCl (controls), mangafodipir, or
calmangafodipir (corresponding in both cases to an accumulated dose of 2800 μmol/kg Mn). Results are expressed as mean ± SEM (n=
17–18 in each group).
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repeated dosing in rats. The total dose in both cases corresponded to
approximately 2800 μmol/kg of Mn (39 × 72 μmol/kg). These results
demonstrate the improved toxicological profile of calmangafodipir in
comparison to that of mangafodipir.
In Vivo Myeloprotective Effects of Calmangafodipir,
Mangafodipir, Teslascan, and MnPLED against Oxaliplatin
A clear dose-response relationship between increasing doses of
oxaliplatin and myelosuppression was evident (Figure 1). As stated in
Materials and Methods section, it was concluded that further experi-
ments testing the myeloprotective effects of calmangafodipir, mangafo-
dipir, Teslascan, and MnPLED should be performed at 12.5 mg/kg
oxaliplatin and that blood cell sample analyses should be performed
the day before and 6 days after oxaliplatin or vehicle administration
in every mice.
The absolute pre-values (day −1) and post-values (day 6) of WBC,
LYM, NEU, and PLC are given in Table 1. The results, presented as
relative differences in cell counts between day −1 and day 6 in each
treatment group, are shown in Figure 5. At an equivalent Mn2+ dose,
i.e., 6.5 μmol/kg (5 mg/kg), calmangafodipir [Ca4Mn(DPDP)5] was
Table 1. Myelosuppressive Effects of a Single Dose of 12.5 mg/kg Oxaliplatin in Untreated BALB/c Mice and in BALB/c Treated with Calmangafodipir [Ca4Mn(DPDP)5], Mangafodipir (MnDPDP),
Teslascan, or MnPLED (Absolute Counts; Mean ± SEM; n = 5).
WBC (109/l) LYM (109/l) NEU (109/l) PLC (109/l)
Day −1 Day 6 Day −1 Day 6 Day −1 Day 6 Day −1 Day 6
Saline; oxaliplatin (12.5 mg/g) 12.6 ± 0.6 2.2 ± 0.2 9.8 ± 0.5 1.6 ± 0.2 2.2 ± 0.2 0.4 ± 0.1 1177 ± 59 473 ± 16
Ca4Mn(DPDP)5 (6.5 μmol/kg); oxaliplatin (12.5 mg/kg) 10.2 ± 0.8 7.3 ± 0.8 7.4 ± 0.8 5.5 ± 0.4 2.3 ± 0.1 1.5 ± 0.4 1038 ± 29 773 ± 143
MnDPDP (1.3 μmol/kg); oxaliplatin (12.5 mg/kg) 10.2 ± 0.5 4.6 ± 0.5 7.7 ± 0.8 3.6 ± 0.4 2.0 ± 0.1 0.9 ± 0.1 957 ± 21 638 ± 117
MnDPDP (13.0 μmol/kg); oxaliplatin (12.5 mg/kg) 11.2 ± 0.6 5.8 ± 0.6 8.8 ± 0.5 4.6 ± 0.5 2.0 ± 0.1 1.0 ± 0.6 908 ± 18 800 ± 100
Teslascan (13.0 μmol/kg); oxaliplatin (12.5 mg/kg) 11.3 ± 0.7 5.2 ± 0.8 9.0 ± 0.6 5.0 ± 0.6 1.8 ± 0.1 1.0 ± 0.2 972 ± 7 693 ± 64
MnPLED (2.0 μmol/kg); oxaliplatin (12.5 mg/kg) 10.1 ± 1.1 7.8 ± 0.7 7.8 ± 0.9 6.4 ± 0.6 1.8 ± 0.2 1.1 ± 0.2 1093 ± 49 857 ± 104
Figure 5.Myeloprotective effects of calmangafodipir, mangafodipir, Teslascan, and MnPLED with regard to (A) WBC, (B) LYM, (C) NEU,
and (D) PLC after oxaliplatin treatment in BALB/c mice. The results are presented as relative differences in cell counts between day −1
and day 6 in each treatment group. Controls received vehicle treatment only. Results expressed as mean ± SEM (n = 5 in each group).
Translational Oncology Vol. 5, No. 6, 2012 Superior Therapeutic Index of Calmangafodipir Karlsson et al. 497
statistically significantly more efficacious than 1.3 μmol/kg (1 mg/kg)
mangafodipir (MnDPDP) to protect the mice from oxaliplatin-
induced fall in total number of WBC (Figure 5A). A single dose
of 12.5 mg/kg oxaliplatin caused the WBC to fall more than 80%,
whereas the fall in animals treated with calmangafodipir was only about
25%. The corresponding fall in mice treated with 1.3 or 13.0 μmol/kg
mangafodipir was around 50%. Teslascan (13.0 μmol/kg, containing
approximately 8 μmol/kg ascorbic acid) gave almost identical results
as those of 13.0 μmol/kg mangafodipir, suggesting that ascorbic acid
at this particular dose does not influence the protective activity of
mangafodipir. Furthermore, the present results presumably also suggest
that mangafodipir has to be dephosphorylated into MnPLED before it
can exert myeloprotective effects—2 μmol/kg MnPLED was, like cal-
mangafodipir, significantly more efficacious than 1.3 and 13.0 μmol/kg
mangafodipir to protect WBC. Similar falls were seen in LYM
(Figure 5B) and in NEU (Figure 5C ) after oxaliplatin treatment, and
the test substances gave qualitatively similar protection. Regarding
PLC, in comparison to WBC, LYM, and NEU, they differed both
in the sensitivity toward oxaliplatin (Figure 1D) and in the cytoprotec-
tive effects of the test substances (Figure 5D).
In the above-described studies, the test substances were adminis-
tered 30 minutes before oxaliplatin and 24 hours after (“double dose”).
However, additional experiments comparing the myeloprotective effect
of 6.5 μmol/kg calmangafodipir given either as double dose (30 min-
utes before oxaliplatin and 24 hours after) or as a single dose (30 min-
utes before oxaliplatin) did not reveal any difference in myeloprotective
efficacy (data not shown).
Cytotoxic Activity of Calmangafodipir, Mangafodipir, Fodipir,
Calfodipir, and Metabolites in CT26 Cells
Oxaliplatin killed the CT26 cells in a concentration-dependent
manner (Figure 6). Neither 10, 30, nor 100 μM fodipir interfered
negatively with the cancer cell killing ability of oxaliplatin. An addi-
tive effect of 10 μM fodipir was seen in the lower concentration range
of oxaliplatin.
When comparing the half-maximal inhibitory concentration (IC50)
ratio between calmangafodipir and mangafodipir, the cytotoxic activ-
ity of fodipir, PLED, calfodipir, or calmangafodipir was about
20 times higher than that of mangafodipir (Figure 7, A and B; Table 2).
MnPLED was six times more potent than mangafodipir (MnDPDP)
in its ability to kill CT26 cancer cells. Neither ZnDPDP, ZnPLED,
nor CaCl2 displayed any cytotoxic activity. Dissociation of Mn
2+ from
DPDP probably explains, to some extent, the cancer killing efficacy
of mangafodipir. Calmangafodipir is, however, almost as efficacious
as fodipir/calfodipir alone, i.e., the killing efficacy of calmangafodipir
is much higher than that of mangafodipir.
The results suggest two important properties. First, PLED is prob-
ably as efficacious as its phosphorylated counterpart fodipir (DPDP)
with respect to its cancer cell killing ability, and second, the lower
in vitro stability of MnPLED in comparison to that of MnDPDP
[26] probably explains the higher efficacy of MnPLED. The lack
of any cytotoxic activity of ZnDPDP and ZnPLED is due to the
1000 times higher stability of these complexes in comparison to their
Mn2+ counterparts [26].
Antitumor Effects of Oxaliplatin in CT26 Tumor–Bearing
Syngenic Mice in the Absence and Presence of Calmangafodipir
In the works on CT26 tumors by Laurent et al. and Alexandre
et al. [12,14] conducted in France, they used a model where they
allowed the tumor to grow to a size exceeding 10 cm3. However, to
ensure accordance with the European Animal Welfare Guideline
2010/63/EU Article 15 and published guidelines, subcutaneous tumors
in mice should not exceed 10% of the animal’s own b.w. Therefore,
similar to recommendations of Workman et al., studies presented here
were finished when tumor volumes exceeded 1.2 cm3 [29]. Since the
CT26 is a fast growing tumor cell line, we had to stop the study 10 days
after inoculation of CT26 cells because several of the tumors at that
time had reached a size of 1 cm3. Such a restriction of course makes
it more difficult to study treatment-related effects on tumor growth.
Nevertheless, we have been able to show a significant difference
between oxaliplatin and non–oxaliplatin-treated CT26 tumor–bearing
syngenic BALB/c mice.
The results are shown in Figures 8 and 9. In the first series of
experiments, the mice received 20 mg/kg oxaliplatin, which is close
to the highest tolerated dose. Single treatment with oxaliplatin resulted
in a statistically significant and more than 50% reduction in tumor
Figure 6. Cytotoxic effects of oxaliplatin in the absence and pres-
ence of various concentrations of DPDP (mean ± SD; n = 3).
Figure 7. Cytotoxic effects of increasing concentrations of (A)
CaCl2, fodipir, calfodipir, and calmangafodipir and (B) ZnDPDP,
ZnPLED, mangafodipir, MnPLED, fodipir, and PLED in CT26 cells
(mean ± SD; n = 3).
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weight. Treatment with calmangafodipir (65.0 μmol/kg) did not
have any negative impact on the antitumor effect of oxaliplatin at a
high dose (Figure 8). However, in a second series of experiments in
which 10 mg/kg oxaliplatin was used, treatment with a relatively
low dose of calmangafodipir (6.5 μmol/kg) resulted in a statistically
significant better antitumor effect (Figure 9); the combined effect of
10 mg/kg oxaliplatin plus 6.5 μmol/kg calmangafodipir was almost
as efficacious as 20 mg/kg oxaliplatin alone. Similar effects were seen
after treatment with 32.5 μmol/kg calmangafodipir.
Discussion
When a relevant diagnostic imaging dose of mangafodipir, i.e., 5 to
10 μmol/kg, is injected into humans [21,22], or as in the present
study into rats, about 80% of the administered Mn2+ is released.
For diagnostic imaging purpose and for occasional therapeutic use,
dissociation of Mn2+ from mangafodipir represents no major toxico-
logical problem. However, for more frequent use, as in therapeutic
use, accumulated Mn toxicity may represent a problem, particularly
when it comes to neurotoxicity [20,30]. Thus, for frequent therapeu-
tic use, as in cancer treatment, compounds that release Mn should be
used with caution.
It is concluded from the present study that replacement of 4/5 of
the Mn2+ with Ca2+ more than doubles the in vivo stability of the
Mn complex. As obvious from the Results section and Figure 4A,
calmangafodipir resulted in significantly and about 40% less retention
of Mn in the brain compared to mangafodipir, after repeated dosing at
more than 30 times the assumed clinical dose in rats. The total dose in
both cases corresponded to approximately 2800 μmol/kg Mn2+ (39 ×
72 μmol/kg). These results demonstrate the improved toxicological
profile of calmangafodipir in comparison to that of mangafodipir.
Furthermore, at equivalent Mn2+ doses, calmangafodipir was signifi-
cantly more efficacious than mangafodipir to protect BALB/c mice
against myelosuppressive effects of the chemotherapy drug oxalipla-
tin. Importantly, calmangafodipir did not interfere negatively with
the antitumor effect of oxaliplatin in CT26 tumor–bearing syngenic
BALB/c mice. On the contrary, it increased the antitumor effect of
oxaliplatin, in a similar way that has been shown with Teslascan
(see below) [12]. The improved in vivo Mn2+ stability of calmangafo-
dipir hence increases its therapeutic index considerably, in comparison
to mangafodipir. MnPLED (2 μmol/kg) was, like calmangafodipir,
significantly more efficacious than 1.3 and 13.0 μmol/kg mangafodipir
to protect WBC, which inevitably suggests that mangafodipir must be
dephosphorylated into MnPLED before it can exert in vivo myelo-
protective effects, in a similar manner that has previously been demon-
strated for its cardioprotective effects [15,25].
From the present data, one cannot fully exclude that the higher
content of fodipir in calmangafodipir compared to mangafodipir
(at an equivalent Mn dose) may have contributed to its higher effi-
cacy. However, the finding that 13 μmol/kg mangafodipir was less
efficacious than 6.5 μmol/kg calmangafodipir does not support such
a suggestion. Furthermore, a recently published study [15] on myo-
cardial protection of mangafodipir and its metabolite MnPLED
Table 2. IC50, Relative Efficacy (Compared to Fodipir), and pD2 Values of the Test Compounds.
Compound IC50 (M) Relative Efficacy IC50 (Fodipir)/IC50 (x*) pD2 (95% Confident Limit)
†
Fodipir 3.123 × 10−5 1.0 4.505 (4.432–4.579)
PLED 3.269 × 10−5 1.0 4.486 (4.439–4.532)
Calmangafodipir 3.351 × 10−5 0.9 4.475 (4.421–4.529)
Calfodipir 3.153 × 10−5 1.0 4.501 (4.436–4.567)
Mangafodipir 6.503 × 10−4 0.05 3.187 (3.103–3.271)
MnPLED 9.628 × 10−5 0.3 4.016 (3.984–4.048)
*Test compound in question.
†pD2 = −log(IC50).
Figure 8. Antitumor effect of a high dose of oxaliplatin (20 mg/kg) in
CT26 tumor–bearing syngenic BALB/c mice in the absence and
presence of a relatively high dose of calmangafodipir (65.0 μmol/kg).
Results expressed asmean ± SEM [n= 10 in vehicle and oxaliplatin
(20 mg/kg) groups; n = 5 in the calmangafodipir group].
Figure 9. Antitumor effect of a low dose of oxaliplatin (10 mg/kg) in
the absence and presence of 6.5 and 32.5 μmol/kg calmangafodipir.
Results are expressed as mean ± SEM (n = 5).
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against detrimental effects of doxorubicin (Adriamycin) does not
indicate any major effect of fodipir or its metabolite PLED. Studies
on the cardioprotective effects of mangafodipir and MnPLED in the
pig [25] inevitably show that the protective effect is an inherent
property of the intact metal complex and not of either dissociated
Mn2+ or fodipir/PLED.
In an ideal world, replacement of 4/5 of the Mn2+ with Ca2+ should
cause all administered Mn2+ to be excreted in the urine. However, the
processes governing the in vivo stability of a metal complex like
mangafodipir are indeed complicated and hence difficult to predict
exactly. Although readily available Zn2+ is a main player in the disso-
ciation process of Mn2+ from fodipir, other metals present in much
higher endogenous concentrations, like Mg2+ and Ca2+, will also
influence the in vivo stability of mangafodipir [27]. Furthermore,
the stability constants with regard to these metals differ between
mangafodipir and its dephosphorylated metabolite MnPLED [26].
Nevertheless, the in vivo stability of Mn2+ in calmangafodipir is
double that of Mn2+ in mangafodipir when tested at an Mn2+ dose
of 10 μmol/kg, as shown in Figure 3. However, at a more clinically
relevant therapeutic dose of Mn2+, i.e., 1 to 2 μmol/kg [17],
corresponding to 5 and 10 μmol/kg of calmangafodipir, the relative
increase in Mn2+ stability will probably be more pronounced. This
presumably explains why calmangafodipir at an equivalent dose of
Mn2+ has an efficacy more than double that of mangafodipir, as evident
from Figure 5.
Zn2+ is present in all body tissues and fluids. The total body Zn2+
content in humans has been estimated to be 2 to 3 g [31]. Plasma
Zn2+ represents about 0.1% of total body Zn2+ content [32], and it
is mainly this small fraction of Zn2+ that competes with Mn2+ for
binding to fodipir or its dephosphorylated counterparts, DPMP and
PLED, after administration. The human body has a high capacity to
maintain Zn homeostasis through synergistic adjustments in gastro-
intestinal absorption and excretion [31]. Clinical phase 1 studies in
humans [21] clearly demonstrated that plasma levels of Zn2+ in humans
return to baseline within 24 hours after receiving 5 or10 μmol/kg
mangafodipir, i.e., a dose expected to consume a similar amount of
Zn2+ as that of 6.5 μmol/kg calmangafodipir. It is therefore no or a
very low risk that repeated injection of clinically relevant doses cal-
mangafodipir should induce Zn deficiency in patients going through
chemotherapy, in case of FOLFOX chemotherapy every second week.
Myelosuppression, in particular neutropenia, is a common dose-
limiting event during cancer treatment with many chemotherapy
drugs, including among others oxaliplatin. Alexandre et al. [14] have
recently shown that 10 mg/kg mangafodipir (Teslascan; corresponding
to 13.0 μmol/kg) via its SOD mimetic activity protects mice against
paclitaxel-induced leukopenia. The present study demonstrates that
6.5 μmol/kg calmangafodipir (corresponding to 1.3 μmol/kg Mn2+)
is considerably more efficacious than 1.3 and 13.0 μmol/kg mangafo-
dipir (corresponding to 1.3 and 13.0 μmol/kg Mn2+, respectively) to
protect against severe oxaliplatin-induced leukopenia. In all their experi-
ments where Laurent et al. and Alexandre et al. [12,14] used mangafo-
dipir, they actually used the ready-to-use contrast formulation, i.e.,
Teslascan, which, in addition to 10 mM mangafodipir, also contains
6 mM antioxidant ascorbic acid. Unfortunately, they did not include
any ascorbic acid controls in any of their experiments. The present
study shows that the Teslascan dose they used in the in vivo experi-
ments, i.e., 10 mg/kg (corresponding to 13.0 μmol/kg), gave more
or less identical results as those obtained in the present study with
13 μmol/kg pure mangafodipir. However, in the same papers, they also
studied effects of such a high concentration as 400 μMTeslascan (con-
taining 240 μM ascorbic acid) in various in vitro systems, and without
any proper ascorbic acid control, it is of course difficult to draw any
clear-cut conclusions from such experiments.
It should be stressed that ascorbic acid is added to the ready-to-use
formulation of mangafodipir (Teslascan) to avoid oxidation of Mn2+
taking place in the vial during storage. However, after in vivo admin-
istration of a clinically relevant dose of Teslascan, ascorbic acid will
have no influence on Mn oxidation. It should also be mentioned that
a freshly made water solution of mangafodipir is stable with respect
to Mn2+ for days without any addition of ascorbic acid. Importantly,
during its dismutating action, Mn catalyzes both a one-electron oxida-
tion and a one-electron reduction and is hence electrically neutral [33].
Accordingly, these reactions typically require no external source of
redox equivalents and are thus self-contained components of the anti-
oxidant machinery, and there is consequently per se no need of a reduc-
ing agent like ascorbic acid.
The previously described myeloprotective effect of Teslascan
against paclitaxel showed that decrease of peripheral NEU and LYM
is accompanied by a parallel decrease in total bone marrow cells [14],
which inevitably suggests that mangafodipir exerts its protective effect
at the level of myelopoiesis.
The reason why mangafodipir and calmangafodipir protects non-
malignant cells but damages cancer cells is far from well understood.
The present paper and a recent paper by Kurz et al. [15] show that the
in vitro cytotoxic activity of mangafodipir is an inherent property of
fodipir or its dephosphorylated counterpart PLED alone and not of
the intact Mn2+ complex. Speculatively, it may be that cancer cells pref-
erably take up the dissociated form of fodipir or its dephosphorylated
counterparts, whereas the intact Mn2+ complex is preferably taken up
by non-malignant cells, in analogy with that described for the anti-
oxidant amifostine [34]. When it comes to the in vivo behavior of
mangafodipir, it seems, however, reasonable to look for additional/
alternative explanations. The complicated in vivo metabolic pattern of
mangafodipir, involving stepwise dephosphorylation and Mn2+ release
[21], makes it difficult to draw conclusions from in vitro experiments.
Some important clues may be obtained from research aiming to
find selective radioprotectants. A body of evidence demonstrates that
overexpression of MnSOD protects non-malignant tissues against
radiation-induced oxidative stress and, interestingly, simultaneously
makes cancer cells more susceptible to radiation [9,10].
However, the experimental and clinical use of SOD enzymes has
been restricted due to large molecular weight and poor cellular uptake
[35]. To circumvent this limitation experimentally, transgenic animal
models have been used to study the radioprotective potential of
MnSOD enzymes. These studies have demonstrated that treating
radiated animal models with MnSOD, delivered by injection of the
enzyme through liposome/viral-mediated gene therapy or insertion of
the human MnSOD gene, can ameliorate radiation-induced damage
[10,36] and simultaneously make cancerous tissue more susceptible to
radiation [9].
It is known that reducedMnSODexpression contributes to increased
DNA damage, and cancer cell lines often have diminished MnSOD
activity compared to normal counterparts [5,37,38]. Mutations within
the MnSOD gene and its regulatory sequence have been observed in
several types of human cancers [5,38–40]. In addition to cancer, muta-
tions in MnSOD are associated with cardiomyopathy and neuronal
diseases, demonstrating the significant role of MnSOD activity in age-
related illnesses [6].
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An elevated oxidative status is indispensable for mitogenic stimu-
lation in transformed cells [41]. A number of studies have reported
that ROS play an important role in promoting tumor metastasis
[8,38,42–45]. These data are consistent with a large body of literature
suggesting that the redox balance of many epithelial tumor cells favors
an elevated oxidant set point [1], including CT26 cells [12,14].
MnSOD is suppressing cell growth in a variety of cancer cell lines
and in mouse models, and the MnSOD growth–retarding functions
are at least partially due to triggering of a p53-dependent cellular
senescence program [46]. Transfection of human MnSOD cDNA
into MCF-7 human breast cancer cells, UACC-903 human mela-
noma cells, SCC-25 human oral squamous carcinoma cells, U118
human glioma cells, and DU145 human prostate carcinoma cells signif-
icantly suppressed their malignant phenotype [40,47–50]. Further-
more, overexpression of MnSOD induced growth arrest in the
human colorectal cancer cell line HCT116 and increased senescence
that required the induction of p53 [46]. Introduction of the normal
MnSOD gene in cancer cells alters the phenotype and the cells lose
the ability to form colonies in culture and tumors in nude mice [47].
Although inflammatory processes secondary to oxidative stress
damage normal tissue, they may, in fact, be beneficial to tumor tissue
by creating growth factor–rich microenvironment and giving the
cancerous clones the need to start growing [7,8]. A striking example
is the existence of tumor-associated macrophages that accumulate
preferentially in the poorly vascularized regions of tumors and secrete
cytokines that actually promote tumor growth [8]. Moreover, not
only can these cytokines promote tumor growth but they have also
been shown to suppress activation of CD8+ T-LYM that are most
efficient in tumor elimination. In fact, there is an increasing interest
for the importance of T-LYM–mediated immune response for the
outcome of cancer chemotherapy [51]. It is known that severe lym-
phopenia (<1000 cells/μl) negatively affects the chemotherapy
response. A collection of mouse cancers, including CT26 colon cancer,
MCA205 fibrosarcomas, TSA cell line breast cancers, GOS cell line
osteosarcomas, and EL4 thymomas, respond to chemotherapy with
doxorubicin and oxaliplatin much more efficiently when they are
implanted in syngenic immune-competent mice than in immune-
deficient hosts, i.e., nude mice [51]. This is in line with clinical studies
revealing that interferon-gamma (IFN-γ)–producing CD8+ T-LYM
are potent cancer immune effectors. Furthermore, a high NEU/LYM
ratio is associated with a low overall survival for patients with advanced
colorectal cancer [52]. Taking into consideration that mangafodipir
and in particular calmangafodipir are highly efficient LYM-protecting
agents during chemotherapy, it is plausible that this property is of
particular importance during in vivo conditions.
From the above discussion, MnSOD appears as an ideal target for
adjunct/supportive treatment in connection with chemotherapy and
radiotherapy—by simultaneously making cancer cells more suscep-
tible to chemotherapy and radiotherapy and by protecting normal
tissue against oxidative damage. Although gene therapy theoretically
may offer a therapeutic possibility, cell permeable low molecular
weight MnSOD mimetics represent a superior alternative. Kensler
et al. described the anticarcinogenic activity of the first generation
of a copper superoxide dismutase (CuSOD) mimetic already in 1983
[53]. They were followed by MnSOD mimetics, particularly of the
so-called metalloporphyrin, salen, and macrocyclic types, and most
recently by the so-called MnPLED derivatives [24,54,55]. A few of the
MnSOD mimetics, including the MnPLED derivative mangafodipir,
have been tested in patients. In a small phase II translational study,
mangafodipir was shown to protect against dose-limiting toxicity of
chemotherapy in cancer patients [17].
Taken together, the present study shows a superior therapeutic
efficacy of calmangafodipir in comparison to mangafodipir, with respect
to selective protection against chemotherapy-induced tissue damage.
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